
CRISPR Therapeutics (CRSP)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy CRISPR Therapeutics (CRSP) Stock
Start investing in CRISPR Therapeutics (CRSP)
About CRISPR Therapeutics (CRSP)
Market cap | $4.2B |
Yesterday's volume | 2.3K |
Revenue (TTM) | $37.68M |
Avg. daily volume | 2.62M |
EBITDA (TTM) | -$455.18M |
Open | $47.86 |
Price / earnings ratio | -10.77x |
Yesterday's range | $47.17 - $51.52 |
Debt / equity | 11.99x |
52 week range | $30.04 - $63.68 |
5 year debt / equity | 9.31x |
Beta (LTM) | 1.33x |
Interest coverage | — |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 15.64x |
Ex-dividend date | — |
Next earnings | Aug 4, 2025 |
Dividend payable date | — |
CRISPR Therapeutics Stock Rating
CRISPR Therapeutics Stock News
View all



Frequently Asked Questions (FAQ)
How to buy CRSP stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in CRSP stock
Navigate to the Explore page. Then, type CRSP into the search bar. When you see CRSP stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased CRSP stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
CRISPR Therapeutics Stock Earnings
The value each CRSP share was expected to gain vs. the value that each CRSP share actually gained.
CRISPR Therapeutics (CRSP) reported Q1 2025 earnings per share (EPS) of -$1.58, missing estimates of -$1.25 by 26.40%. In the same quarter last year, CRISPR Therapeutics's earnings per share (EPS) was -$1.43. CRISPR Therapeutics is expected to release next earnings on 08/04/2025, with an earnings per share (EPS) estimate of -$1.46.